Skip to main content
Top
Published in: Clinical Rheumatology 11/2014

01-11-2014 | Original Article

Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model

Authors: Xiaoli Mao, Yunyun Wu, Huitian Diao, Jianlei Hao, Gaofei Tian, Zhenghu Jia, Zheng Li, Sidong Xiong, Zhenzhou Wu, Puyue Wang, Liqing Zhao, Zhinan Yin

Published in: Clinical Rheumatology | Issue 11/2014

Login to get access

Abstract

Our aim is to reveal the role of interleukin 6 (IL-6) in the pathogenesis of systemic lupus erythematosus (SLE) in a murine model of SLE. Normal female C57BL/6 mice were immunized with syngeneic-activated lymphocyte-derived DNA (ALD-DNA) to induce SLE. Non-immunized mice were used as control. SLE-associated markers, including anti-double-stranded DNA (anti-dsDNA) Abs, urine protein, and kidney histopathology, were assayed to ensure the induction of the disease. Compared with control mice, ALD-DNA immunized mice exhibited high levels of anti-dsDNA Abs, IL-6 expression in vivo and in vitro. We also found that IL-6 knockout (IL-6KO) mice were resistant to ALD-DNA-induced SLE. The activation of CD4+ T cells in immunized IL-6KO mice was lower than in immunized wild-type (Wt) mice. Intracellular cytokine staining showed that Foxp3 expression in immunized IL-6KO mice was higher than in immunized Wt mice, which might be associated with the disease severity. We further discovered that ALD-DNA-stimulated dendritic cells supernatants could result in higher IL-6 and TNF-α expression and could suppress Foxp3 expression. In addition, blocking IL-6 could up-regulate Foxp3 expression. Therefore, our findings show that IL-6 promotes the progression of SLE via suppressing Treg differentiation.
Literature
1.
go back to reference Tan EM (1989) Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151PubMedCrossRef Tan EM (1989) Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151PubMedCrossRef
2.
go back to reference Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, Datta SK, Madaio MP (1992) Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 41(6):1690–1700PubMedCrossRef Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, Datta SK, Madaio MP (1992) Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 41(6):1690–1700PubMedCrossRef
3.
go back to reference Tebbe B, Orfanos CE (1997) Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 6(2):96–104PubMedCrossRef Tebbe B, Orfanos CE (1997) Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 6(2):96–104PubMedCrossRef
4.
go back to reference Qiao B, Wu J, Chu YW, Wang Y, Wang DP, Wu HS, Xiong SD (2005) Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology (Oxford) 44(9):1108–1114CrossRef Qiao B, Wu J, Chu YW, Wang Y, Wang DP, Wu HS, Xiong SD (2005) Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology (Oxford) 44(9):1108–1114CrossRef
5.
go back to reference Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, Xiong SD (2007) DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46(12):1796–1803CrossRef Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, Xiong SD (2007) DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46(12):1796–1803CrossRef
6.
go back to reference Wen Z, Xu L, Xu W, Xiong S (2012) Production of anti-double-stranded DNA antibodies in activated lymphocyte derived DNA induced lupus model was dependent on CD4+ T cells. Lupus 21(5):508–516PubMedCrossRef Wen Z, Xu L, Xu W, Xiong S (2012) Production of anti-double-stranded DNA antibodies in activated lymphocyte derived DNA induced lupus model was dependent on CD4+ T cells. Lupus 21(5):508–516PubMedCrossRef
7.
go back to reference Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA (2001) Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6):705–714PubMedCrossRef Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA (2001) Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6):705–714PubMedCrossRef
8.
9.
go back to reference al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S (1993) Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 13(1):58–67PubMedCrossRef al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S (1993) Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 13(1):58–67PubMedCrossRef
10.
go back to reference Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147(1):117–123PubMed Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147(1):117–123PubMed
12.
go back to reference Smolen JS, Steiner G, Aringer M (2005) Anti-cytokine therapy in systemic lupus erythematosus. Lupus 14(3):189–191PubMedCrossRef Smolen JS, Steiner G, Aringer M (2005) Anti-cytokine therapy in systemic lupus erythematosus. Lupus 14(3):189–191PubMedCrossRef
13.
go back to reference Qian Y, Conway KL, Lu X, Seitz HM, Matsushima GK, Clarke SH (2006) Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased frequency of apoptotic lymphocytes and a defect in macrophage clearance. Blood 108(3):974–982PubMedCrossRefPubMedCentral Qian Y, Conway KL, Lu X, Seitz HM, Matsushima GK, Clarke SH (2006) Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased frequency of apoptotic lymphocytes and a defect in macrophage clearance. Blood 108(3):974–982PubMedCrossRefPubMedCentral
14.
go back to reference Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M, Lukacs NW, Chensue SW, Kunkel SL (2009) TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. J Clin Invest 119(1):33–46PubMedPubMedCentral Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M, Lukacs NW, Chensue SW, Kunkel SL (2009) TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. J Clin Invest 119(1):33–46PubMedPubMedCentral
15.
go back to reference Zhang W, Xu W, Xiong S (2010) Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol 184(11):6465–6478PubMedCrossRef Zhang W, Xu W, Xiong S (2010) Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol 184(11):6465–6478PubMedCrossRef
16.
go back to reference Zhang W, Xu W, Xiong S (2011) Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 187(4):1764–1777PubMedCrossRef Zhang W, Xu W, Xiong S (2011) Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 187(4):1764–1777PubMedCrossRef
17.
go back to reference Zhang W, Wu J, Qiao B, Xu W, Xiong S (2011) Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS ONE 6(7):e22659PubMedCrossRefPubMedCentral Zhang W, Wu J, Qiao B, Xu W, Xiong S (2011) Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS ONE 6(7):e22659PubMedCrossRefPubMedCentral
18.
go back to reference Mevorach D, Zhou JL, Song X, Elkon KB (1998) Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 188(2):387–392PubMedCrossRefPubMedCentral Mevorach D, Zhou JL, Song X, Elkon KB (1998) Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 188(2):387–392PubMedCrossRefPubMedCentral
19.
go back to reference Yin Z, Zhang DH, Welte T, Bahtiyar G, Jung S, Liu L, Fu XY, Ray A, Craft J (2000) Dominance of IL-12 over IL-4 in gamma delta T cell differentiation leads to default production of IFN-gamma: failure to down-regulate IL-12 receptor beta 2-chain expression. J Immunol 164(6):3056–3064PubMedCrossRef Yin Z, Zhang DH, Welte T, Bahtiyar G, Jung S, Liu L, Fu XY, Ray A, Craft J (2000) Dominance of IL-12 over IL-4 in gamma delta T cell differentiation leads to default production of IFN-gamma: failure to down-regulate IL-12 receptor beta 2-chain expression. J Immunol 164(6):3056–3064PubMedCrossRef
20.
go back to reference Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S (2013) Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS ONE 8(3):e58161PubMedCrossRefPubMedCentral Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S (2013) Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS ONE 8(3):e58161PubMedCrossRefPubMedCentral
21.
go back to reference Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, Mayadas TN, Illei GG, Siebenlist U (2012) Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 37(6):1104–1115PubMedCrossRefPubMedCentral Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, Mayadas TN, Illei GG, Siebenlist U (2012) Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 37(6):1104–1115PubMedCrossRefPubMedCentral
22.
go back to reference Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151–1164PubMed Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151–1164PubMed
24.
go back to reference Nath SK, Kilpatrick J, Harley JB (2004) Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 16(6):794–800PubMedCrossRef Nath SK, Kilpatrick J, Harley JB (2004) Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 16(6):794–800PubMedCrossRef
25.
go back to reference Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I (2000) Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18(5):565–570PubMed Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I (2000) Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18(5):565–570PubMed
26.
go back to reference Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11(5):613–624PubMedCrossRef Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11(5):613–624PubMedCrossRef
27.
go back to reference Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C (2003) IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24(1):25–29PubMedCrossRef Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C (2003) IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24(1):25–29PubMedCrossRef
28.
go back to reference Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, Gonzalez-Amaro R (2006) Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 27(2):110–118PubMedCrossRef Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, Gonzalez-Amaro R (2006) Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 27(2):110–118PubMedCrossRef
29.
go back to reference Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S (2005) Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 202(10):1333–1339PubMedCrossRefPubMedCentral Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S (2005) Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 202(10):1333–1339PubMedCrossRefPubMedCentral
30.
go back to reference Garrett-Sinha LA, John S, Gaffen SL (2008) IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 20(5):519–525PubMedCrossRef Garrett-Sinha LA, John S, Gaffen SL (2008) IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 20(5):519–525PubMedCrossRef
Metadata
Title
Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model
Authors
Xiaoli Mao
Yunyun Wu
Huitian Diao
Jianlei Hao
Gaofei Tian
Zhenghu Jia
Zheng Li
Sidong Xiong
Zhenzhou Wu
Puyue Wang
Liqing Zhao
Zhinan Yin
Publication date
01-11-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 11/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2717-9

Other articles of this Issue 11/2014

Clinical Rheumatology 11/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.